Company profile: Poxel
1.1 - Company Overview
Company description
- Provider of biopharmaceutical products for metabolic diseases, focusing on type 2 diabetes and NASH. Portfolio includes TWYMEEG (Imeglimin), approved in Japan for type 2 diabetes, targeting mitochondrial dysfunction; PXL065, a deuterium-stabilized R-pioglitazone for NASH with Phase 2 primary endpoint met; and PXL770, a direct AMPK activator for rare diseases including NASH and ALD.
Products and services
- PXL065: Engineered as deuterium-stabilized R-pioglitazone targeting non-alcoholic steatohepatitis (NASH), Phase 2-validated by meeting its primary endpoint in a Phase 2 trial
- PXL770: A mechanism-specific, direct AMPK activator focused on rare diseases, including non-alcoholic steatohepatitis (NASH) and adrenoleukodystrophy (ALD), enabling targeted enzyme activation
- TWYMEEG (Imeglimin): A Japan-approved, mitochondria-targeted medication for the treatment of type 2 diabetes, specifically targeting mitochondrial dysfunction in patients in Japan
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Poxel
Diasome
HQ: United States
Website
- Description: Provider of insulin-based, liver-targeted diabetes therapeutics utilizing Hepatocyte Directed Vesicles (HDV) to enhance insulin delivery and reduce hypoglycemia risk. The company conducts multiple Phase 2 studies, including OPTI-2 and ISLE-1 Phase 2b trials, the Good to Great study, and an insulin pump crossover study, evaluating HDV added to rapid-acting insulin in patients with Type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diasome company profile →
Intarcia
HQ: United States
Website
- Description: Provider of long-term therapies for chronic diseases, offering the MEDICITM Drug Delivery System for twice-yearly subcutaneous osmotic implants, ITCA 650 (twice-yearly exenatide implant) for type 2 diabetes, and an Ionic Liquid Platform converting injectable biologics and peptides into oral therapies; pipeline includes i2o-105s (long-acting GLP-1 receptor agonist), i2o-107 (long-acting amylin), and i2o-110 (dual agonist) for type 2 diabetes, obesity, and NASH.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intarcia company profile →
Fractyl Health
HQ: United States
Website
- Description: Provider of curative therapies for metabolic diseases, including Revita, a therapy designed to modify duodenal dysfunction via hydrothermal ablation to restore metabolic health, and Rejuva, a preclinical AAV gene therapy platform aimed at improving islet function for long-term remission of T2D and obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fractyl Health company profile →
Ypsomed
HQ: Switzerland
Website
- Description: Provider of injection and infusion systems for self-medication, partnering with pharmaceutical and biotechnology companies for injection pens and autoinjectors. Delivers mylife Diabetescare solutions including infusion systems, blood glucose monitoring and therapy management, the mylife YpsoPump insulin pump, YpsoMate autoinjector, and mylife Loop automated insulin dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ypsomed company profile →
Modulim
HQ: United States
Website
- Description: Provider of light-based imaging and care management solutions: Clarifi Imaging System, a non-contact, noninvasive tool using spatial frequency domain imaging to assess microvascular health by measuring tissue oxygenation and perfusion; LAMP, integrating patient assessment, data management, and care coordination; Modulim Cloud, a HIPAA-compliant platform for secure data and imaging; and Magnifi Software for tailored views and remote care collaboration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modulim company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Poxel
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Poxel
2.2 - Growth funds investing in similar companies to Poxel
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Poxel
4.2 - Public trading comparable groups for Poxel
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →